Mindray snaps up Chinese analytic systems maker; FDA collaboration to monitor eye condition associated with cataract surgery;

> Mindray Medical International ($MR) has agreed to buy a controlling stake in Hunan Changsha Tiandiren Biotech. It has not disclosed any terms of the deal. Report

> The FDA and other organizations unveiled a program to monitor medical devices used in cataract surgery in an effort to stem outbreaks of a rare, inflammatory condition associated with the procedure. FDA release

> Nanosphere ($NSPH) has obtained CE IVD Mark for its gram-positive blood culture nucleic acid test on the automated sample-to-result Verigene system. Nanosphere release

> Women with Poly Implant Prothese breast implants made by a now-defunct French company have no reason to have them removed but should seek medical advice if they believe they have ruptured, British health officials said. Item

> Mindray Medical International ($MR) has entered an agreement with Novation allowing the latter's more than 65,000 members and affiliates to purchase the M7 and M5 ultrasound systems. Mindray release

> The state of Maryland is being urged to require "rigorous internal and external review of stenting practices in hospitals in the state after an advisory group recommended a lower standard." The call comes after The Baltimore Sun reported John Chung-Yee Wang of the Union Memorial Hospital in Baltimore is accused of improper stenting in three separate legal claims. News

> The Austen BioInnovation Institute in Akron and the FDA are collaborating to support and develop regulatory science for the safe and effective use of biomaterials in medical devices. Release

And Finally... Former NFL star Willie Gault has been accused by U.S. regulators of taking part in a scheme to artificially inflate the stock of a medical device company he managed. Report

Suggested Articles

Longitude Capital invests in what its founders call “transformative healthcare companies," working in areas they hope will increase quality of life.

The FDA launched a center of excellence to oversee digital health products such as smartphone apps, wearable devices and software-based treatments.

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.